Abion Inc. Share Price

A203400

KR7203400007

Biotechnology & Medical Research

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
676.00 ^KRW	-2.03%		-.--%	-78.40%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 Significant Split/Dividend

More about the company

Stock Market
Stocks
A203400 Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	60.91B 43.84M 38.23M 36.1M 32.78M 61.42M 4.21B 61.67M 432M 167M 2.14B 165M 161M 6.88B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	32.57B 23.45M 20.45M 19.31M 17.53M 32.85M 2.25B 32.98M 231M 89.24M 1.14B 88.08M 86.13M 3.68B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	73.67%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
29/12/24	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
25/12/24	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
22/12/24	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
22/12/24	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
17/12/24	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
04/12/24	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
04/12/24	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
10/11/24	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
10/11/24	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
27/10/24	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
27/12/23	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-2.03%
3 months	-37.87%
6 months	-75.46%
Current year	-78.40%

Current year	570	4,335
1 year	570	4,510
3 years	570	7,277.78
5 years	570	13,194.44
10 years	570	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	31/07/2010
Seong-Yun Woo DFI	Director of Finance/CFO	45	27/03/2025
Gi-Ryong Jang COO	Chief Operating Officer	46	31/12/2025

Abion Inc. Share Price

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news: Abion Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	30/12/2014
Jin-Wook Yang BRD	Director/Board Member	56	24/03/2022
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.	Importance
08/12/25	Sun-mi Chang	Free	27	0.0001%	-
08/12/25	Yang-mi Lim	Buy	115	0.0002%
08/12/25	Yang-mi Lim	Free	92	0.0002%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-2.03%	-.--%	-76.60%	-83.03%	43.84M
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+47.13%	+99.00%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	-1.26%	-7.81%	+156.15%	+320.43%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.24B
Average	-0.73%	-0.48%	+24.71%	+178.30%	27.49B
Weighted average by Cap.	-0.47%	+1.44%	+35.36%	+147.69%

	2024	2025
Net sales	760M 547K 477K 450K 409K 766K 52.47M 769K 5.39M 2.08M 26.68M 2.05M 2.01M 85.84M	880M 634K 552K 522K 474K 887K 60.79M 891K 6.25M 2.41M 30.91M 2.38M 2.33M 99.45M
Net income	-43.38B -31.23M -27.23M -25.71M -23.35M -43.74M -3B -43.93M -308M -119M -1.52B -117M -115M -4.9B	-29.06B -20.92M -18.24M -17.23M -15.64M -29.31M -2.01B -29.43M -206M -79.62M -1.02B -78.59M -76.84M -3.28B
Net Debt	14.05B 10.11M 8.82M 8.33M 7.56M 14.16M 970M 14.22M 99.72M 38.48M 493M 37.98M 37.14M 1.59B	-28.33B -20.4M -17.78M -16.79M -15.25M -28.57M -1.96B -28.69M -201M -77.62M -995M -76.61M -74.91M -3.2B